Stock Events

Stock Events

PharmaCyte Biotech 

€22.50
13
+€0.00+0% Tuesday 20:00

Statistics

Day High
0.015
Day Low
0.015
52W High
22.5
52W Low
0.015
Volume
2,000
Avg. Volume
0
Mkt Cap
241.55M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

16DecExpected
Q2 2023
Q2 2026
Next
-0.08
0.25
0.58
0.92
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-20.08MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow EFY.MU. It's not an investment recommendation.
Apple
4
AAPL
NVIDIA
4
NVDA
Tesla
3
TSLA
Alphabet
3
GOOG

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.24B
CRISPR Therapeutics is involved in gene editing, a cutting-edge area of biotech that could compete with PharmaCyte's cell-based therapies for treating cancer and diabetes.
Editas Medicine
EDIT
Mkt Cap396.24M
Editas Medicine operates in the genome editing space, directly competing with PharmaCyte's efforts in developing novel treatments for serious diseases.
Intellia Therapeutics
NTLA
Mkt Cap1.65B
Intellia Therapeutics is another key player in the CRISPR/Cas9 technology space, potentially competing in the development of therapies for diseases PharmaCyte targets.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.66B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, potentially competing across several of PharmaCyte's interest areas.
Vertex Pharmaceuticals
VRTX
Mkt Cap133.37B
Vertex Pharmaceuticals is known for its work in treating cystic fibrosis and other serious diseases, which could intersect with PharmaCyte's therapeutic areas.
Alnylam Pharmaceuticals
ALNY
Mkt Cap34.25B
Alnylam Pharmaceuticals is a leader in RNAi (RNA interference) therapeutics, competing in the broader biotech space for novel treatments.
Sarepta Therapeutics
SRPT
Mkt Cap1.97B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics, presenting competition in innovative treatment approaches.

About

PharmaCyte Biotech Inc is a biotechnology company focused on developing cellular therapies for cancer based on its proprietary cellulose-based live cell encapsulation technology, Cell-in-a-Box. The technology is intended to be used as a platform for therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC). The current generation of the Company's product candidate is CypCaps. The Company is preparing to commercialize cellular therapies for cancer and advance clinical research and development, including a clinical trial in LAPC using encapsulated live cells. Its candidate therapy involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active, cancer-killing form.
Show more...
CEO
Joshua N. Silverman
Employees
2
Country
United States
ISIN
US71715X2036

Listings

MU
DE
EFY.MU
XNAS
US
PMCB
BOATS
BOATS
PMCB.BOATS

0 Comments

Share your thoughts

FAQ

What is PharmaCyte Biotech stock price today?▼
The current price of EFY.MU is €22.50 EUR — it has increased by +0% in the past 24 hours. Watch PharmaCyte Biotech stock price performance more closely on the chart.
What is PharmaCyte Biotech stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Muenchen exchange PharmaCyte Biotech stocks are traded under the ticker EFY.MU.
Is PharmaCyte Biotech stock price growing?▼
EFY.MU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year PharmaCyte Biotech has showed a +0% increase.
What is PharmaCyte Biotech market cap?▼
Today PharmaCyte Biotech has the market capitalization of 241.55M
When is the next PharmaCyte Biotech earnings date?▼
PharmaCyte Biotech is going to release the next earnings report on December 16, 2026.
What is PharmaCyte Biotech revenue for the last year?▼
PharmaCyte Biotech revenue for the last year amounts to 0 EUR.
What is PharmaCyte Biotech net income for the last year?▼
EFY.MU net income for the last year is -20.08M EUR.
How many employees does PharmaCyte Biotech have?▼
As of September 30, 2026, the company has 2 employees.
In which sector is PharmaCyte Biotech located?▼
PharmaCyte Biotech operates in the Health & Wellness sector.
When did PharmaCyte Biotech complete a stock split?▼
The last stock split for PharmaCyte Biotech was on July 12, 2021 with a ratio of 1:1500.
Where is PharmaCyte Biotech headquartered?▼
PharmaCyte Biotech is headquartered in LAS VEGAS, United States.